Marshall Islands vs Palau: Prevalence rate of obesity in adults
Marshall Islands
42.0%
in 2024
Palau
40.5%
in 2024
Marshall Islands rank
18th
Palau rank
20th
Prevalence rate of obesity in adults over time
- Marshall Islands
- Palau
How they compare
Marshall Islands currently reports 42.0% against 40.5% in Palau, a difference of 1.5%.
Across all 45 years both countries report, Marshall Islands has been ahead every year.
Marshall Islands ranks 18th and Palau ranks 20th of 199 countries.
Marshall Islands has averaged higher in every one of the 5 decades both report.
Head to head by decade
| Decade | Marshall Islands | Palau | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 30.4% | 29.3% | 1.1% | Marshall Islands |
| 1990s | 35.4% | 34.4% | 1.0% | Marshall Islands |
| 2000s | 38.6% | 37.5% | 1.1% | Marshall Islands |
| 2010s | 40.7% | 39.3% | 1.4% | Marshall Islands |
| 2020s | 41.7% | 40.2% | 1.5% | Marshall Islands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, Marshall Islands or Palau?
- Marshall Islands, at 42.0% against 40.5% in Palau as of 2024.
- What is the difference in prevalence rate of obesity in adults between Marshall Islands and Palau?
- 1.5%, with Marshall Islands ahead.
- How many years of comparable data are there for Marshall Islands and Palau?
- 45 years are reported by both, from 1980 to 2024.
- How do Marshall Islands and Palau rank globally for prevalence rate of obesity in adults?
- Marshall Islands ranks 18th and Palau ranks 20th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.